Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension

Clinical Therapeutics

Volumn 18, Issue 3, 1996, Pages 411-428

  Weir, Matthew R ^a,c   Elkins, Michelle ^b   Liss, Charles ^b   Vrecenak, Arthur J ^b   Barr, Eliav ^b   Edelman, Jonathan M ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LOSARTAN; LOSARTAN POTASSIUM; NIFEDIPINE; PLACEBO;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EDEMA; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SITTING; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0029977211     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80022-1     Document Type: Article

References (16)

1. Dzau VJ. Evolving concepts of the renin-angiotensin system. Focus on renal and vascular mechanisms. Am J Hypertens. 1988;19:334S-337S.
2. Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven Press; 1990:1987.
3. Bernstein KE, Berk BC. The biology of angiotensin II receptors. Am J Kidney Dis. 1993;22:745-754.
4. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardial. 1995;75:793-795.
5. Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens. 1995;8:578-583.
6. Gradham AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25: 1345-1350.
7. Romero JC, Raij L, Granger JP, et al. Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension. 1987;10:140-151.
8. Levine S, Croog SH. What constitutes quality of life? A conceptualization of the dimensions of life quality in healthy populations and patients with cardiovascular disease. In: Wenger NK, Mattson ME, Furberg CD, Elinson J, eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq Publishing, Inc; 1984:46-58.
9. Dahlof C. Well being (quality of life) in connection with hypertensive treatment. Clin Cardiol. 1991;14:97-103.
10. Alemayehu D, Lefkowitz M, Carr AA. Low-dose drug combination therapy: An alternative first-line approach to hypertension treatment. Am Heart J. 1995;130: 359-366.
11. Frohlich ED, Grim C, Labarthe DR, et al. Recommendations for Human Blood Pressure Determination by Sphygmomanometers: Report of a Special Task Force Appointed by the Steering Committee, American Heart Association. Dallas: American Heart Association; 1987.
12. Wenger NK, Mattson ME, Furberg CD, eds. Overview: Assessment of quality of life in clinical trials of cardiovascular therapies. In: Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq Publishing, Inc; 1984:1-12.
13. Loutzenhiser R. Mechanisms of action of calcium antagonists. In: Epstein M, Loutzenhiser R, eds. Calcium Antagonists and the Kidney. Philadelphia: Hanley & Belfus, Inc; 1990:1-22.
14. Hall JE, Guyton AC. Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven Press; 1990:1105-1130.
15. Freis ED, Reda DM, Materson BJ. Volume (weight) loss and blood pressure response following thiazide diuretics. Hypertension. 1988;12:244-250.
16. Davila D, Davila T. Thiazide diuretics inhibit contractions of isolated smooth muscles. Pharmacology. 1981;22:108-112.